RSS 1.0Centre for Immunobiology
Browse by
The Centre for Immunobiology combines top-quality research and education in immunology, with particular focus on acute and chronic inflammatory disease, lymphocyte development, and the mucosal immune system.
Recent Submissions
-
Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti-platelet therapy
(Wiley, 2020-04-11)BACKGROUND: Endothelium-derived prostacyclin and nitric oxide elevate platelet cyclic nucleotide levels and maintain quiescence. We previously demonstrated that a synergistic relationship exists between cyclic nucleotides ... -
Senescent cells evade immune clearance via HLA-E-mediated NK and CD8(+) T cell inhibition
(Springer Nature, 2019-06-03)Senescent cells accumulate in human tissues during ageing and contribute to age-related pathologies. The mechanisms responsible for their accumulation are unclear. Here we show that senescent dermal fibroblasts express ... -
The RIG‐I‐like receptor LGP2 inhibits Dicer‐dependent processing of long double‐stranded RNA and blocks RNA interference in mammalian cells
(EMBO, 2018-02-15)In vertebrates, the presence of viral RNA in the cytosol is sensed by members of the RIG ‐I‐like receptor (RLR ) family, which signal to induce production of type I interferons (IFN ). These key antiviral cytokines act in ... -
Recent advances in gut immunology
(2017-06) -
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients.
(2019-10-01)V565 is an engineered TNFα-neutralising single domain antibody formulated into enteric coated mini-tablets to enable release in the intestine after oral administration as a possible oral treatment for inflammatory bowel ... -
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2.
(Springer Nature, 2020-03-20)Proteolysis-Targeting Chimeras (PROTACs) are heterobifunctional small-molecules that can promote the rapid and selective proteasome-mediated degradation of intracellular proteins through the recruitment of E3 ligase complexes ... -
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.
(2019-07-02)RIP2 kinase has been identified as a key signal transduction partner in the NOD2 pathway contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-molecule inhibitors of RIP2 ... -
Homeostasis of the gut barrier and potential biomarkers
(American Physiological Society, 2017-03-01)The gut barrier plays a crucial role by spatially compartmentalizing bacteria to the lumen through the production of secreted mucus and is fortified by the production of secretory IgA (sIgA) and antimicrobial peptides and ... -
KDM2 proteins constrain transcription from CpG island gene promoters independently of their histone demethylase activity
(Oxford University Press, 2019-07-31)ABSTRACT CpG islands (CGI) are associated with the majority of mammalian gene promoters and function to recruit chromatin modifying enzymes. It has therefore been proposed that CGIs regulate gene expression through ... -
KDM2 proteins constrain transcription from CpG island gene promoters independently of their histone demethylase activity
(Oxford University Press, 2019-09-26)CpG islands (CGIs) are associated with the majority of mammalian gene promoters and function to recruit chromatin modifying enzymes. It has therefore been proposed that CGIs regulate gene expression through chromatin-based ... -
Germs and germlines: how "public" B-cell clones evolve in the gut.
(2020-05-16)Chen et al. describe how B-cell clones observed in the gut of many different individuals (recurrent or "public" clonotypes) are shaped by the combined influences of common microbial antigens and underlying genomic recombination ... -
SOLUBLE GUANYLATE CYCLASE ACTIVATORS AS COMBINATION ANTI-PLATELET THERAPY WITH P2Y12 INHIBITORS AND PDE INHIBITORS: IN VIVO AND EX VIVO STUDIES
(BMJ Publishing Group Ltd, 2016-06-03)Methods Mice were pre-treated with vehicle, prasugrel (0.3 mg/kg), cinaciguat (0.3 mg/kg) + dipyridamole (2.0 mg/kg), or prasugrel + cinaciguat + dipyridamole (triple) and anesthetized. To measure in vivo thrombus formation, ...
